コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 onas vaginalis, vaginitis or cervicitis, and male circumcision.
2 trials as well as new studies pertaining to male circumcision.
3 of HIV-infected men resuming sex early after male circumcision.
4 re prophylaxis (PrEP), and voluntary medical male circumcision.
5 e most culturally-appropriate way to promote male circumcision.
6 ure prophylaxis (PrEP) and voluntary medical male circumcision.
7 unt testing would increase uptake of ART and male circumcision.
8 o generate new policy statements on neonatal male circumcision.
9 a generalized HIV epidemic and low rates of male circumcision.
11 ant decreases in condom use occurred in both male circumcision acceptors (-9.2% with all partners and
12 ption were observed in both groups (-7.8% in male circumcision acceptors and -6.1% in nonacceptors),
13 comes estimate that 3.3% (P < 0.0001) of the male circumcision acceptors reduced their engagement in
14 m use (adjIRR, 0.56 [95% CI, 0.36-0.89]) and male circumcision (adjIRR, 0.70 [95% CI, 0.55-0.91]), an
15 ged >40 years to those aged 15-19 years) and male circumcision (adjPRR = 0.60; 95% CI = 0.47-0.77) an
16 tudies have indicated a protective effect of male circumcision against acquisition of human immunodef
20 vidence of risk compensation associated with male circumcision among this cohort of men during 3 year
21 great emphasis on the following: scale-up of male circumcision and early ART initiation with outreach
23 insertive anal sex, the association between male circumcision and HIV was protective but not statist
25 ewed the evidence for an association between male circumcision and Human Papillomavirus (HPV) infecti
26 0.69; k = 3).Neither the association between male circumcision and other STIs (odds ratio, 1.06; 95%
27 studies have reported an association between male circumcision and reduced risk of HIV infection in f
28 have also investigated associations between male circumcision and risk of acquisition of HIV and sex
29 ys were used as model inputs for traditional male circumcision and scale-up of voluntary medical male
30 ledge, attitudes and practices about medical male circumcision and their understandings of partial ef
32 review all evidence on associations between male circumcision and women's health outcomes to benefit
33 publications reporting associations between male circumcision and women's health outcomes up to Apri
35 ntions to reduce new HIV infections, such as male circumcision, and on demand creation for early trea
36 eaders had a substantial effect on uptake of male circumcision, and should be considered as part of m
37 care, antiretroviral therapy (ART) use, and male circumcision, and the primary biologic outcome of H
38 can increase HIV testing rates and voluntary male circumcision, and they can improve other HIV preven
44 of behaviour change, condom use, and medical male circumcision, as well as expanded use of antiretrov
46 nd genital factors of the transmitter (i.e., male circumcision, bacterial vaginosis, and use of acycl
48 ave sex with men and sex workers), including male circumcision, behavioral interventions, and chemopr
52 though most providers had heard that medical male circumcision can reduce risk of HIV acquisition in
54 62 (28%) of 224 men were circumcised in the male circumcision clinic referral group compared with 13
55 ly treat people living with HIV, and support male circumcision could increase population levels of HI
58 onfirmed, these results suggest that medical male circumcision could substantially reduce incidence o
59 posure prophylaxis, condom distribution, and male circumcision, could avert a further 150 000 new inf
62 13 of 3870) to 96% (4526 of 4738; p<0.0001); male circumcision coverage increased from 35% (698 of 20
63 rendemic setting but did not clearly improve male circumcision coverage or HIV viral suppression.
67 hty-one percent of the men self-selected for male circumcision during the period, and their sociodemo
68 xisting interventions (promoting condom use, male circumcision, early antiretroviral therapy [ART] in
71 from the PLOS Collection "Voluntary Medical Male Circumcision for HIV Prevention: Improving Quality,
73 the ages of 15 and 49 years in two trials of male circumcision for the prevention of HIV and other se
74 ondom promotion, antiretroviral therapy, and male circumcision) for key populations and the wider pop
77 idence interval, 0.22-2.28; k=4) [corrected].Male circumcision had a protective association with HIV
84 ering combinations of male condom use, adult male circumcision, HIV testing, and early antiretroviral
85 an African countries plan to scale-up infant male circumcision (IMC) for cost-efficient HIV preventio
89 g data from a randomized controlled trial of male circumcision in Kisumu, Kenya, adjusted mean surviv
90 However, the comparable protective effect of male circumcision in MSM studies conducted before the er
93 rol trials have demonstrated the efficacy of male circumcision in reducing the incidence of HIV infec
95 e attesting to the effectiveness of clinical male circumcision in the prevention of HIV/AIDS transmis
96 age women about the risks and limitations of male circumcision, in addition to the benefits, should b
97 ong people living with HIV and prevalence of male circumcision, including traditional circumcision.
98 lation levels of ART, viral suppression, and male circumcision increased from baseline in both groups
99 ientific, religious, and cultural aspects of male circumcision (intervention group), or standard outr
106 us studies examining the association between male circumcision (MC) and human papillomavirus (HPV) in
107 A randomized trial of voluntary medical male circumcision (MC) of HIV-infected men reported incr
108 Randomized trials have demonstrated that male circumcision (MC) reduces heterosexual acquisition
109 different intervention models for promoting male circumcision (MC) to prevent HIV transmission in We
110 ort study of 221 HIV-infected men undergoing male circumcision (MC) was conducted in Rakai, Uganda.
113 e estimated the 72-month efficacy of medical male circumcision (MMC) against herpes simplex virus 2 (
115 lower cost by increasing coverage of medical male circumcision (MMC) and antiretroviral treatment (AR
119 rica demonstrating the protective effects of male circumcision on HIV infection, studies have reporte
122 proximity (<60 km) and the time that a free male circumcision outreach campaign from the Tanzanian M
124 sk factors (partner plasma viral load, STIs, male circumcision, pregnancy) were integrated with the S
125 line of providers' understandings of medical male circumcision prior to roll-out, and can be used to
126 mcision, and should be considered as part of male circumcision programmes in other sub-Saharan Africa
128 y evidence was found for five outcomes, with male circumcision protecting against cervical cancer, ce
129 Medium-consistency evidence was found for male circumcision protecting against human papillomaviru
130 s of MSM revealed insufficient evidence that male circumcision protects against HIV infection or othe
131 n men participating in a randomized trial of male circumcision provided exfoliated penile cells from
133 tructural strategies have made a difference--male circumcision provides substantial protection from s
140 als and meta-analyses have demonstrated that male circumcision reduces men's risk of contracting huma
144 gical and observational studies suggest that male circumcision reduces the risk of HIV acquisition in
145 vs. 37% reduction), which is consistent with male circumcision scale-up and higher levels of female a
147 tiretroviral therapy (ART), and strengthened male circumcision services, and 15 received standard of
149 r sociodemographic factors, sexual behavior, male circumcision, sexually transmitted infections, preg
151 o decreasing the incidence of HIV infection, male circumcision significantly reduced the incidence of
156 d to consider collaboration with traditional male circumcision (TMC) providers when planning for VMMC
159 antiretroviral therapy and voluntary medical male circumcision, to estimate changes in the age distri
160 s and 209 HIV-positive couples enrolled in a male circumcision trial in Rakai, Uganda, using the Roch
161 )-negative couples followed for 2 years in a male circumcision trial in Rakai, Uganda, using the Roch
162 ial data collected during 2007-2011 on 2,137 male circumcision trial participants who were uncircumci
164 ive antiretroviral therapy, as in the recent male circumcision trials of heterosexual African men, su
165 tion of ART adherence, and voluntary medical male circumcision via community HIV care providers for t
166 nt-reported use of ART, participant-reported male circumcision, viral-load suppression, and sexual be
167 y of demand generation for voluntary medical male circumcision (VMMC) among 15-29 year-old males in Z
168 of steps for cascades for voluntary medical male circumcision (VMMC) and for partner reduction or co
171 to increase the uptake of voluntary medical male circumcision (VMMC) in sub-Saharan Africa and enhan
173 Countries participating in voluntary medical male circumcision (VMMC) scale-up have adopted most of s
179 10% increase in the community prevalence of male circumcision was associated with a decrease in pate
182 ntercourse; and, in three randomised trials, male circumcision was protective against HIV acquisition
183 independent randomised controlled trials of male circumcision, we enrolled HIV-negative men and thei
187 sh whether educating religious leaders about male circumcision would increase uptake in their village